The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex Pharmaceuticals' (NASDAQ:VRTX) non-opioid pain medicine Journavx (suzetrigine). One of ...

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

The availability of suzetrigine may represent a critical step in addressing the nation’s pain management crisis. While ...

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

Vertex Pharmaceuticals has multiple growth drivers with potentially more on the way. Yo-yos are fun for kids. But yo-yo stock ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

Walmart's "everyday low prices" should attract customers even if a recession comes. Which group of individuals is in the best ...

The opioid crisis has claimed the lives of over half a million Americans since the beginning of the epidemic, a process ...

Vertex Pharmaceuticals Incorporated (NASDAQ ... and recently launched two new approved therapies: Alyftrek and Journavx. Alyfrtek is an improvement to VRTX’s CF portfolio, offering a once ...

The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex Pharmaceuticals' (NASDAQ:VRTX) non-opioid pain medicine Journavx (suzetrigine).

Casgevy and Journavx are poised to become significant growth drivers for Vertex Pharmaceuticals in the coming years, marking pivotal steps in the company's push to diversify its portfolio.